Sugi Predict

Sugi Predict / Targets / USP8

USP8

Ubiquitin carboxyl-terminal hydrolase 8 · P40818 · USP8 on Sugi Atlas →

6,219 patent compounds predicted against USP8, 3,064 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5421819 SCHEMBL5421819 0.59 19/20
SCHEMBL5421821 SCHEMBL5421821 0.59 19/20
SCHEMBL5426587 SCHEMBL5426587 0.55 19/20
SCHEMBL1512505 SCHEMBL1512505 1.00 18/20
SCHEMBL4382629 SCHEMBL4382629 0.72 18/20
SCHEMBL1512360 SCHEMBL1512360 0.67 18/20
SCHEMBL4599977 SCHEMBL4599977 0.62 18/20
SCHEMBL2682639 SCHEMBL2682639 0.58 18/20
SCHEMBL1512403 SCHEMBL1512403 1.00 17/20
SCHEMBL1512480 SCHEMBL1512480 1.00 17/20
SCHEMBL1512483 SCHEMBL1512483 1.00 17/20
SCHEMBL1512485 SCHEMBL1512485 1.00 17/20
SCHEMBL1512498 SCHEMBL1512498 1.00 17/20
SCHEMBL1512560 SCHEMBL1512560 1.00 17/20
SCHEMBL1512579 SCHEMBL1512579 1.00 17/20
SCHEMBL1512580 SCHEMBL1512580 1.00 17/20
SCHEMBL1512607 SCHEMBL1512607 1.00 17/20
SCHEMBL4600925 SCHEMBL4600925 0.83 17/20
SCHEMBL4599545 SCHEMBL4599545 0.78 17/20
SCHEMBL1512451 SCHEMBL1512451 0.69 17/20

Clinical trials — most relevant to USP8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma nanUNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates nanCOMPLETED
Inherited Reproductive Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a USP8 binder may also engage these)

ProteinNameSimilarity
Q80U87 — 1.000 Q80U87 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.991 landscape →
O43150 — 0.990 O43150 →
Q8NDI1 — 0.990 Q8NDI1 →
P48193 — 0.989 P48193 →
A6QP06 — 0.988 A6QP06 →
D3ZA12 — 0.988 D3ZA12 →
Q8BX57 — 0.988 Q8BX57 →
U2SURP U2 snRNP-associated SURP motif-containing protein 0.988 landscape →
A3KFM7 — 0.988 A3KFM7 →
O75061 — 0.988 O75061 →
P97496 — 0.988 P97496 →
Q7Z3E5 — 0.988 Q7Z3E5 →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.988 landscape →
Q8C0D4 — 0.988 Q8C0D4 →
EPB41 Protein 4.1 0.987 landscape →
Q7SIG6 — 0.987 Q7SIG6 →
DHX29 ATP-dependent RNA helicase DHX29 0.987 landscape →
Q28E45 — 0.987 Q28E45 →
F1NBT0 — 0.987 F1NBT0 →
Q1LYM3 — 0.987 Q1LYM3 →
Q2QMH1 — 0.987 Q2QMH1 →
ARHGEF12 Rho guanine nucleotide exchange factor 12 0.987 landscape →
Q8WML3 — 0.987 Q8WML3 →
Q8BMD7 — 0.987 Q8BMD7 →
F7BJB9 — 0.987 F7BJB9 →
PTPN13 Tyrosine-protein phosphatase non-receptor type 13 0.987 landscape →
Q641G3 — 0.987 Q641G3 →
Q6PDG5 — 0.987 Q6PDG5 →
Q69ZW3 — 0.986 Q69ZW3 →